MX2009007023A - Agonistas de receptores heterociclicos para el tratamiento de diabetes y trastornos metabolicos. - Google Patents
Agonistas de receptores heterociclicos para el tratamiento de diabetes y trastornos metabolicos.Info
- Publication number
- MX2009007023A MX2009007023A MX2009007023A MX2009007023A MX2009007023A MX 2009007023 A MX2009007023 A MX 2009007023A MX 2009007023 A MX2009007023 A MX 2009007023A MX 2009007023 A MX2009007023 A MX 2009007023A MX 2009007023 A MX2009007023 A MX 2009007023A
- Authority
- MX
- Mexico
- Prior art keywords
- diabetes
- treatment
- receptor agonists
- metabolic disorders
- heterocyclic
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87790306P | 2006-12-28 | 2006-12-28 | |
| US11/964,461 US7638541B2 (en) | 2006-12-28 | 2007-12-26 | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| PCT/US2007/088978 WO2008083238A2 (en) | 2006-12-28 | 2007-12-27 | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009007023A true MX2009007023A (es) | 2009-09-09 |
Family
ID=39589206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009007023A MX2009007023A (es) | 2006-12-28 | 2007-12-27 | Agonistas de receptores heterociclicos para el tratamiento de diabetes y trastornos metabolicos. |
Country Status (13)
| Country | Link |
|---|---|
| US (8) | US7638541B2 (enExample) |
| EP (1) | EP2111107B1 (enExample) |
| JP (1) | JP5455645B2 (enExample) |
| KR (1) | KR101539308B1 (enExample) |
| AU (1) | AU2007339772B9 (enExample) |
| BR (1) | BRPI0720675A2 (enExample) |
| CA (1) | CA2672725C (enExample) |
| EA (1) | EA016720B1 (enExample) |
| ES (1) | ES2405105T3 (enExample) |
| IL (1) | IL199397A (enExample) |
| MX (1) | MX2009007023A (enExample) |
| NZ (1) | NZ577996A (enExample) |
| WO (1) | WO2008083238A2 (enExample) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| GB0610746D0 (en) * | 2006-06-01 | 2006-07-12 | Prosidion Ltd | Method of treatment |
| US7638541B2 (en) * | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| ES2352880T3 (es) * | 2007-03-08 | 2011-02-23 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de gpr119. |
| US7751907B2 (en) | 2007-05-24 | 2010-07-06 | Smiths Medical Asd, Inc. | Expert system for insulin pump therapy |
| US8221345B2 (en) | 2007-05-30 | 2012-07-17 | Smiths Medical Asd, Inc. | Insulin pump based expert system |
| EP2185544B1 (en) | 2007-07-19 | 2014-11-26 | Cymabay Therapeutics, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders |
| DE102007047735A1 (de) * | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Thiazolderivate |
| US20090177147A1 (en) | 2008-01-07 | 2009-07-09 | Michael Blomquist | Insulin pump with insulin therapy coaching |
| CA2719507C (en) * | 2008-03-31 | 2018-03-27 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| AU2009271414A1 (en) * | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl GPR119 agonists and uses thereof |
| US8536176B2 (en) * | 2008-08-01 | 2013-09-17 | Nippon Chemiphar Co., Ltd. | GPR119 agonist |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| BRPI0919288A2 (pt) | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | teriapia de combinação para tratamento de diabetes e condições relacionadas. |
| MX2011003151A (es) * | 2008-10-01 | 2011-04-27 | Bayer Cropscience Ag | Tiazoles sustituidos con heterociclilo como agentes fitosanitarios. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| US20110160222A1 (en) * | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR076936A1 (es) * | 2009-06-02 | 2011-07-20 | Vitae Pharmaceuticals Inc | Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1 |
| JP5538528B2 (ja) * | 2009-06-18 | 2014-07-02 | カディラ・ヘルスケア・リミテッド | 新規なｇｐｒ１１９アゴニスト |
| EP2272846A1 (de) * | 2009-06-23 | 2011-01-12 | Bayer CropScience AG | Thiazolylpiperidin Derivate als Fungizide |
| BR112012000831A2 (pt) | 2009-06-24 | 2019-09-24 | Boehringer Ingelheim Int | compostos, composições farmacêuticas e métodos relacionados |
| TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| JP2011006366A (ja) * | 2009-06-26 | 2011-01-13 | Sanwa Kagaku Kenkyusho Co Ltd | 新規チオフェンカルボキサミド誘導体及びその医薬用途 |
| AR077638A1 (es) * | 2009-07-15 | 2011-09-14 | Lilly Co Eli | Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad |
| EP2483281B1 (en) | 2009-10-01 | 2014-06-04 | Cymabay Therapeutics, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| CN102712634B (zh) * | 2009-10-30 | 2016-04-06 | 拜耳知识产权有限责任公司 | 杂芳基哌啶和杂芳基哌嗪衍生物 |
| PH12012501037A1 (en) | 2009-11-27 | 2013-01-14 | Boehringer Ingelheim Int | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| US8882701B2 (en) | 2009-12-04 | 2014-11-11 | Smiths Medical Asd, Inc. | Advanced step therapy delivery for an ambulatory infusion pump and system |
| JP2013047188A (ja) * | 2009-12-24 | 2013-03-07 | Nippon Chemiphar Co Ltd | Ｇｐｒ１１９作動薬 |
| KR20120130104A (ko) | 2010-02-01 | 2012-11-28 | 닛뽕 케미파 가부시키가이샤 | Ｇｐｒ119 작동약 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| CA2797310C (en) | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Glp-1 receptor agonist and dpp-4 inhibitor combination therapy |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| GB2488360A (en) * | 2011-02-25 | 2012-08-29 | Prosidion Ltd | Heterocyclic GPCR agonists |
| WO2011153435A1 (en) * | 2010-06-04 | 2011-12-08 | Metabolex, Inc. | Preparation of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| BR112012032248A2 (pt) * | 2010-06-23 | 2016-09-13 | Metabolex Inc | composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| PL2625177T3 (pl) | 2010-10-08 | 2015-12-31 | Cadila Healthcare Ltd | Nowi agoniści GPR 119 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| WO2012086735A1 (ja) * | 2010-12-22 | 2012-06-28 | 大正製薬株式会社 | 縮合複素環化合物 |
| AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
| ES2713566T3 (es) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| AU2012340622A1 (en) * | 2011-11-23 | 2014-05-22 | The Board Of Regents Of The University Of Texas System | Isoxazole treatments for diabetes |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| CN104540835B (zh) | 2012-04-26 | 2017-08-08 | 百时美施贵宝公司 | 用于治疗血小板聚集的作为蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑衍生物 |
| WO2013163241A1 (en) | 2012-04-26 | 2013-10-31 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| TWI572605B (zh) | 2012-04-26 | 2017-03-01 | 必治妥美雅史谷比公司 | 血小板聚集之抑制劑 |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| US9238100B2 (en) | 2012-06-07 | 2016-01-19 | Tandem Diabetes Care, Inc. | Device and method for training users of ambulatory medical devices |
| CN105814037B (zh) | 2013-12-17 | 2018-11-30 | 默克专利股份公司 | 作为丙酮酸脱氢酶激酶的抑制剂的n1-(3,3,3-三氟-2-羟基-2-甲基丙酰基)-哌啶衍生物 |
| EP3092235A2 (en) | 2014-01-06 | 2016-11-16 | Rhizen Pharmaceuticals S.A. | Novel inhibitors of glutaminase |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| KR101651505B1 (ko) | 2014-05-02 | 2016-08-29 | 현대약품 주식회사 | 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| CN107074805B (zh) | 2014-07-03 | 2021-02-26 | 德州大学系统董事会 | 用于治疗疾病的gls1抑制剂 |
| EP3300500B9 (en) | 2015-05-20 | 2021-01-13 | Amgen Inc. | Triazole agonists of the apj receptor |
| EP3316887B1 (en) | 2015-06-30 | 2020-04-08 | Board of Regents, The University of Texas System | Gls1 inhibitors for treating disease |
| KR101763533B1 (ko) | 2015-11-04 | 2017-07-31 | 현대약품 주식회사 | 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| US10150753B2 (en) | 2015-12-22 | 2018-12-11 | Board Of Regents, The University Of Texas System | Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide |
| US10569016B2 (en) | 2015-12-29 | 2020-02-25 | Tandem Diabetes Care, Inc. | System and method for switching between closed loop and open loop control of an ambulatory infusion pump |
| EP3436443B1 (en) | 2016-03-29 | 2020-03-11 | Merck Patent GmbH | N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase |
| US10428024B2 (en) | 2016-04-28 | 2019-10-01 | Merck Patent Gmbh | Piperidinyl derivatives |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| EP3468967B1 (en) * | 2016-06-09 | 2023-07-26 | Pramana Pharmaceuticals Inc. | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119 |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| WO2018026890A1 (en) | 2016-08-03 | 2018-02-08 | Cymabay Therapeutics | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| WO2018097944A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| EP3541810B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| EP3541802B1 (en) | 2016-11-16 | 2025-01-01 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| JP7361687B2 (ja) | 2017-10-18 | 2023-10-16 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | グルタミナーゼ阻害薬療法 |
| US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
Family Cites Families (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3108117A (en) | 1959-02-12 | 1963-10-22 | Mead Johnson & Co | 3-benzyl-1, 2-diloweralkyl-3-pyrrolidinols |
| US3778443A (en) | 1969-02-13 | 1973-12-11 | Ciba Geigy Ag | 4-tetrahydro pyridyl,hydroxy alkyl pyrazoles |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| DE2701705A1 (de) | 1976-01-28 | 1977-08-04 | Sandoz Ag | Neue organische verbindungen, ihre verwendung und herstellung |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JP2527107B2 (ja) | 1991-04-16 | 1996-08-21 | 日本新薬株式会社 | 固体分散体の製造方法 |
| US5817667A (en) | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
| US5187677A (en) | 1991-08-23 | 1993-02-16 | Hewlett-Packard Company | Waveform synthesizer through simulating multiplication |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| AU4444393A (en) | 1992-09-01 | 1994-03-10 | Zeneca Limited | Pyrrolidine derivatives |
| GB9310713D0 (en) | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Aryl substituted heterocycles |
| ATE279406T1 (de) | 1995-01-12 | 2004-10-15 | Glaxo Group Ltd | Piperidinderivate mit tachykinin-antagonistischer wirkung |
| US6048876A (en) | 1995-01-23 | 2000-04-11 | Suntory Limited | Medicament for the alleviation or treatment of symptom derived from ischemic disease and compound useful therefor |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| DE19519496A1 (de) | 1995-05-27 | 1996-11-28 | Lau Matthias Dipl Ing | Sauerstoffsensitives Einschichtsystem und Verfahren zur Anordnung des Systems |
| KR100384979B1 (ko) | 1995-09-07 | 2003-10-17 | 에프. 호프만-라 로슈 아게 | 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘 |
| US5792769A (en) | 1995-09-29 | 1998-08-11 | 3-Dimensional Pharmaceuticals, Inc. | Guanidino protease inhibitors |
| JPH11513382A (ja) | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| KR100537843B1 (ko) | 1996-07-22 | 2006-04-28 | 다이이치 아스비오파마 가부시키가이샤 | 아릴피페리디놀및아릴피페리딘유도체및이들을함유하는약제 |
| EP0915875B1 (en) | 1996-07-25 | 2003-04-09 | MERCK SHARP & DOHME LTD. | Substituted triazolo-pyridazine derivatives as ligands for gaba receptors |
| US5880138A (en) | 1996-10-01 | 1999-03-09 | Eli Lilly And Company | NMDA receptor selective antagonists |
| IT1297894B1 (it) | 1997-07-23 | 1999-12-20 | C T A Srl | Apparecchiatura automatica per il lavaggio, disinfezione, asciugatura e stimolazione dei capezzoli di animali da latte. |
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| DE69941777D1 (de) | 1998-03-10 | 2010-01-21 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| US6274735B1 (en) | 1998-08-10 | 2001-08-14 | Hoffmann-La Roche Inc. | Process and intermediates for preparation of substituted piperidines |
| IT1303737B1 (it) | 1998-11-11 | 2001-02-23 | Smithkline Beecham Spa | Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1. |
| PT1133559E (pt) | 1998-11-20 | 2005-10-31 | Arena Pharm Inc | Receptor acoplato a proteina g orfao humano, rup3 |
| US20030017528A1 (en) | 1998-11-20 | 2003-01-23 | Ruoping Chen | Human orphan G protein-coupled receptors |
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| HRP20010738B1 (en) | 1999-03-15 | 2005-02-28 | Axys Pharmaceuticals | N-cyanomethyl amides as protease inhibitors |
| GB9912416D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| US6015712A (en) | 1999-07-19 | 2000-01-18 | Isis Pharmaceuticals Inc. | Antisense modulation of FADD expression |
| AR035016A1 (es) * | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| GB9923177D0 (en) | 1999-09-30 | 1999-12-01 | Pfizer Ltd | Novel polypeptide |
| IL139073A0 (en) | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
| EP1176147A1 (en) | 2000-07-28 | 2002-01-30 | Pfizer Limited | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof |
| US6784185B2 (en) | 2001-03-16 | 2004-08-31 | Pfizer Inc. | Pharmaceutically active compounds |
| US6770645B2 (en) | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
| US20030095958A1 (en) | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
| US20030003157A1 (en) | 2001-06-06 | 2003-01-02 | University Of Medicine & Dentistry Of New Jersey | Collagen compositions and methods for making and using the same |
| WO2003014110A1 (en) | 2001-08-08 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Benzazepine derivative, process for producing the same, and use |
| AU2003224632A1 (en) * | 2002-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Hppars activators |
| JPWO2003091216A1 (ja) | 2002-04-25 | 2005-09-02 | 住友製薬株式会社 | 新規ピペリジン誘導体 |
| US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7576074B2 (en) * | 2002-07-15 | 2009-08-18 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
| US7084145B2 (en) * | 2002-10-25 | 2006-08-01 | Pfizer Inc. | Triazole compounds useful in therapy |
| GB0224919D0 (en) * | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
| GB0230162D0 (en) | 2002-12-24 | 2003-02-05 | Metris Therapeutics Ltd | Compounds useful in inhibiting angiogenesis |
| ES2316964T3 (es) | 2003-02-24 | 2009-04-16 | Arena Pharmaceuticals, Inc. | Fenil-y piridilpipereidinia-derivados como moduladores del metabolismo de la glucosa. |
| ES2268341T3 (es) | 2003-03-05 | 2007-03-16 | Maus S.P.A. | Metodo para mecanizar un disco de freno. |
| GB0308333D0 (en) | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
| BRPI0409949A (pt) | 2003-05-01 | 2006-04-25 | Bristol Myers Squibb Co | compostos de pirazol amida aril-substituìda úteis como inibidores de cinase |
| CA2525325A1 (en) | 2003-05-01 | 2004-11-18 | Abbott Laboratories | Pyrazole-amides and sulfonamides as sodium channel modulators |
| US20040220170A1 (en) | 2003-05-01 | 2004-11-04 | Atkinson Robert N. | Pyrazole-amides and sulfonamides as sodium channel modulators |
| MXPA05013474A (es) | 2003-06-13 | 2006-03-09 | Schering Ag | Derivados de quinolilamida como antagonistas de ccr-5. |
| US7132426B2 (en) * | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| CN1829718A (zh) | 2003-07-14 | 2006-09-06 | 艾尼纳制药公司 | 作为新陈代谢调节剂的稠合芳基和杂芳基衍生物以及预防和治疗与其相关的病症 |
| KR20060036105A (ko) | 2003-07-29 | 2006-04-27 | 제논 파마슈티칼스 인크. | 피리딜 유도체 및 그의 치료제로서의 용도 |
| FR2862647B1 (fr) | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| NZ547965A (en) | 2003-12-24 | 2009-12-24 | Prosidion Ltd | 1,2,4-Oxadiazole derivatives as GPCR receptor agonists |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| JP4787529B2 (ja) | 2004-04-09 | 2011-10-05 | 大塚製薬株式会社 | 医薬組成物 |
| CN101027560A (zh) * | 2004-04-13 | 2007-08-29 | 艾尼纳制药公司 | 用于治疗高血糖症和相关病症的人类g蛋白偶合受体及其调节物 |
| DE102004020186A1 (de) | 2004-04-22 | 2005-11-17 | Aventis Pharma Deutschland Gmbh | Heterocyclylessigsäuren als Inhibitoren von TAFla |
| US8710232B2 (en) | 2004-04-22 | 2014-04-29 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives used as TAFIa inhibitors |
| AU2005251909A1 (en) | 2004-06-08 | 2005-12-22 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| PT1852433E (pt) | 2004-10-29 | 2012-02-08 | Zeria Pharm Co Ltd | Derivados de carbazole, seus solvatos ou seus sais farmaceuticamente aceitáveis |
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| US20080051418A1 (en) | 2004-11-26 | 2008-02-28 | Tsuyoshi Maekawa | Arylalkanoic Acid Derivative |
| US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| GB0428526D0 (en) | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
| WO2006073167A1 (ja) * | 2005-01-07 | 2006-07-13 | Ono Pharmaceutical Co., Ltd. | ピロリジン誘導体 |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| US8277495B2 (en) | 2005-01-13 | 2012-10-02 | Candela Corporation | Method and apparatus for treating a diseased nail |
| AU2006216941B2 (en) | 2005-02-16 | 2009-12-03 | Pharmacopeia, Llc | Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity |
| GB0504850D0 (en) | 2005-03-09 | 2005-04-13 | Novartis Ag | Organic compounds |
| US20060206074A1 (en) | 2005-03-11 | 2006-09-14 | The Procter & Gamble Company | Absorbent core structures having undulations |
| EP1707202A1 (de) | 2005-03-31 | 2006-10-04 | Speedel Experimenta AG | Organische Verbindungen |
| KR100712289B1 (ko) | 2005-04-07 | 2007-04-27 | 삼성에스디아이 주식회사 | 평판표시장치 및 그의 제조방법 |
| EP1888529A2 (en) | 2005-05-18 | 2008-02-20 | Wyeth | 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same |
| EP1888512A2 (en) * | 2005-06-06 | 2008-02-20 | Smithkline Beecham Corporation | Chemical compounds |
| CA2611216A1 (en) | 2005-06-15 | 2006-12-21 | Pfizer Limited | 3-phenylazetidine derivatives as dopamine agonists |
| WO2007023507A2 (en) | 2005-06-20 | 2007-03-01 | Wockhardt Limited | Oxazolidinones bearing antimicrobial activity composition and methods of preparation |
| JP5114395B2 (ja) | 2005-06-30 | 2013-01-09 | プロシディオン・リミテッド | Ｇｐｃｒアゴニスト |
| JP2008545008A (ja) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Ｇｐｃｒアゴニスト |
| TW200738701A (en) | 2005-07-26 | 2007-10-16 | Du Pont | Fungicidal carboxamides |
| JP2007045752A (ja) | 2005-08-10 | 2007-02-22 | Takeda Chem Ind Ltd | ５員芳香族複素環誘導体、その製造法および用途 |
| ATE429430T1 (de) | 2005-09-16 | 2009-05-15 | Arena Pharm Inc | Stoffwechselmodulatoren und behandlung damit verbundener erkrankungen |
| BRPI0617207A2 (pt) | 2005-09-29 | 2011-07-19 | Sanofi Aventis | derivados de fenil-1,2,4-oxadiazolona, processos para sua preparação e seu uso como produtos farmacêuticos |
| JP5201817B2 (ja) * | 2005-10-28 | 2013-06-05 | 大塚製薬株式会社 | 医薬組成物 |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| ATE552245T1 (de) | 2006-05-15 | 2012-04-15 | Merck Sharp & Dohme | Antidiabetische bicyclische verbindungen |
| FR2902767B1 (fr) | 2006-06-22 | 2008-09-19 | J P B Creations Sa | Dispositif de conditionnement d'un produit a base de colle |
| DE602007010458D1 (de) | 2006-06-23 | 2010-12-23 | Basf Se | Reversible thermochrome zusammensetzungen |
| EP2043744A2 (en) | 2006-07-13 | 2009-04-08 | SmithKline Beecham Corporation | Chemical compounds |
| US20080103141A1 (en) | 2006-08-30 | 2008-05-01 | Biovitrum | New compounds |
| EP2094683B1 (en) | 2006-12-06 | 2011-10-12 | GlaxoSmithKline LLC | Bicyclic compounds and use as antidiabetics |
| WO2008073929A1 (en) * | 2006-12-11 | 2008-06-19 | Wyeth | Ion channel modulators |
| MX2009006232A (es) | 2006-12-11 | 2009-06-22 | Wyeth Corp | Derivados de carboxamida como moduladores del canal de ion. |
| SI2120932T1 (sl) | 2006-12-20 | 2014-09-30 | Nerviano Medical Sciences S.R.L. | Indazolni derivati kot kinazni inhibitorji za zdravljenje raka |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| ZA200904281B (en) | 2006-12-28 | 2010-08-25 | Metabolex Inc | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders |
| ES2352880T3 (es) | 2007-03-08 | 2011-02-23 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de gpr119. |
| JP2010526146A (ja) | 2007-05-04 | 2010-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | ［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト |
| DE602008005582D1 (de) | 2007-05-10 | 2011-04-28 | Glaxo Group Ltd | Pyrazolderivate als p2x7-modulatoren |
| EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
| UY31232A1 (es) | 2007-07-19 | 2009-03-02 | Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones | |
| CN101801958B (zh) | 2007-07-19 | 2014-01-29 | 默沙东公司 | 作为蛋白质激酶抑制剂的杂环酰胺化合物 |
| FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| JP2010533672A (ja) | 2007-07-19 | 2010-10-28 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ヘテロシクリル化合物およびケモカインアンタゴニストとしてのそれらの使用 |
| DK2019104T3 (da) | 2007-07-19 | 2013-12-16 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf |
| EP2185544B1 (en) | 2007-07-19 | 2014-11-26 | Cymabay Therapeutics, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders |
| WO2009070869A1 (en) | 2007-12-04 | 2009-06-11 | Merck Frosst Canada Ltd. | Renin inhibitors |
| CA2719507C (en) | 2008-03-31 | 2018-03-27 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| AU2009271414A1 (en) | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl GPR119 agonists and uses thereof |
| US8536176B2 (en) | 2008-08-01 | 2013-09-17 | Nippon Chemiphar Co., Ltd. | GPR119 agonist |
| BRPI0919288A2 (pt) | 2008-09-10 | 2015-12-15 | Boehring Ingelheim Internat Gmbh | teriapia de combinação para tratamento de diabetes e condições relacionadas. |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US20110160222A1 (en) | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
| EP2483281B1 (en) | 2009-10-01 | 2014-06-04 | Cymabay Therapeutics, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| WO2011153435A1 (en) | 2010-06-04 | 2011-12-08 | Metabolex, Inc. | Preparation of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| BR112012032248A2 (pt) | 2010-06-23 | 2016-09-13 | Metabolex Inc | composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
-
2007
- 2007-12-26 US US11/964,461 patent/US7638541B2/en active Active
- 2007-12-27 NZ NZ577996A patent/NZ577996A/en not_active IP Right Cessation
- 2007-12-27 KR KR1020097015460A patent/KR101539308B1/ko not_active Expired - Fee Related
- 2007-12-27 BR BRPI0720675-5A patent/BRPI0720675A2/pt not_active Application Discontinuation
- 2007-12-27 JP JP2009544271A patent/JP5455645B2/ja not_active Expired - Fee Related
- 2007-12-27 EP EP07869989.9A patent/EP2111107B1/en active Active
- 2007-12-27 MX MX2009007023A patent/MX2009007023A/es active IP Right Grant
- 2007-12-27 AU AU2007339772A patent/AU2007339772B9/en not_active Ceased
- 2007-12-27 EA EA200900896A patent/EA016720B1/ru not_active IP Right Cessation
- 2007-12-27 ES ES07869989T patent/ES2405105T3/es active Active
- 2007-12-27 WO PCT/US2007/088978 patent/WO2008083238A2/en not_active Ceased
- 2007-12-27 CA CA2672725A patent/CA2672725C/en active Active
-
2009
- 2009-06-17 IL IL199397A patent/IL199397A/en active IP Right Grant
- 2009-08-14 US US12/541,865 patent/US8227495B2/en not_active Expired - Fee Related
- 2009-11-16 US US12/619,577 patent/US8288384B2/en not_active Expired - Fee Related
-
2012
- 2012-09-12 US US13/612,451 patent/US8975258B2/en active Active
-
2013
- 2013-01-16 US US13/743,166 patent/US8921350B2/en active Active
-
2015
- 2015-02-19 US US14/626,749 patent/US20150239881A1/en not_active Abandoned
-
2016
- 2016-10-25 US US15/333,416 patent/US9737537B2/en not_active Expired - Fee Related
-
2017
- 2017-07-26 US US15/659,808 patent/US9925189B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009007023A (es) | Agonistas de receptores heterociclicos para el tratamiento de diabetes y trastornos metabolicos. | |
| MX2011006574A (es) | Agonistas del receptor gpr120 y usos de los mismos. | |
| UA107917C2 (ru) | Арильный агонист рецептора gpr120 и его применение | |
| TW200833688A (en) | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | |
| WO2009014910A3 (en) | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders | |
| MX2010013876A (es) | Agonistas de arilo grpr119 y sus usos . | |
| WO2010029089A3 (en) | Combination therapy for the treatment of diabetes and related conditions | |
| AU2007221366A8 (en) | Oxyntomodulin derivatives | |
| UA98629C2 (ru) | Соединения и способ модуляции киназ | |
| UA97817C2 (ru) | Гетероциклические производные 4-(метилсульфонил)фенила и их применение | |
| ZA200807789B (en) | Neuromedin U receptor agonists and uses thereof | |
| WO2008008887A3 (en) | Gpr119 agonists for treating metabolic disorders | |
| WO2007003962A3 (en) | Gpcr agonists | |
| WO2007003961A3 (en) | Gpcr agonists | |
| WO2007127505A3 (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
| WO2007116229A8 (en) | Heterocyclic gpcr agonists | |
| MX2009007180A (es) | Agonistas del receptor acoplado a la proteina g de la piperidina. | |
| WO2010123930A3 (en) | Chemosensory receptor ligand-based therapies | |
| CO6361917A2 (es) | Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico | |
| WO2008008286A3 (en) | Substituted pyrazoles as ghrelin receptor antagonists | |
| AU2008317057A8 (en) | Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119 | |
| PT2040755E (pt) | Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6 | |
| GB0812642D0 (en) | Compounds | |
| IL186566A0 (en) | Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels | |
| WO2011147951A8 (en) | Cycloamino derivatives as gpr119 agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration | ||
| HC | Change of company name or juridical status |